| Document |
Document Title |
|
WO/2015/158191A1 |
Disclosed is a method for stereoselectively synthesizing hypolipidemic drug ezetimibe (I), comprising the following steps: a) an 4-(4-fluorobenzoyl)-1-butanoic acid (II) reacts with a chiral auxiliary (III) to obtain a ketone of a formul...
|
|
WO/2015/153683A1 |
This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses me...
|
|
WO/2015/133405A1 |
[Problem] To provide a novel stereoselective method for manufacturing an optically active azetidinone compound. [Solution] Provided is an industrially useful manufacturing method capable of manufacturing an optically active azetidinone c...
|
|
WO/2015/129859A1 |
[Problem] To provide a novel compound having an S1P1 receptor-antagonizing effect. [Solution] Provided are a compound represented by general formula (I): (in the formula, R1, R2, and R3 are each a hydrogen atom, halogen atom, C1-6 alkyl ...
|
|
WO/2015/123465A1 |
The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
|
|
WO/2015/123437A1 |
The present invention is directed to cyclopropylamine derivatives of formula I which are LSDl inhibitors useful in the treatment of diseases such as cancer.
|
|
WO/2015/105131A1 |
Provided is a cationic lipid which can be used for nucleic acid delivery to a cytoplasm and which is capable of solving the problem of physical stability of a lipid complex. This cationic lipid is a compound represented by general formul...
|
|
WO/2015/103583A1 |
Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the mon...
|
|
WO/2015/097475A1 |
The present invention relates to compounds of formula (I) shown below: wherein Q is as defined herein. The compounds of formula (I) act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The pr...
|
|
WO/2015/092448A1 |
The present invention relates to the novel compounds represented by Formula (la) or (lb) and to their pharmaceutical preparations for the treatment of atherosclerosis and cholesterol level reduction.
|
|
WO/2015/095340A1 |
This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipi...
|
|
WO/2015/086428A1 |
An effective process of making adamantanamide, which process is fast, does not the use of organic solvents or labor-intensive isolation or purification of the product, by removal of organic solvent or by-products, and has improved yield ...
|
|
WO/2015/085153A1 |
The present invention relates to phenoxy-azetidine derivatives of Formula I, processes for preparing them, pharmaceutical compositions containing them, and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2015/078374A1 |
The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as desc...
|
|
WO/2015/070394A1 |
The present invention relates to a method for preparing a penem antibiotic intermediate. The method comprises the following steps: step 1: preparing an intermediate compound by means of a Mannich reaction; and step 2: converting the inte...
|
|
WO/2015/073547A1 |
The present invention relates to disubstituted phenoxy azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2015/061518A1 |
Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula :(I)
|
|
WO/2015/061407A1 |
Methods for the synthesis of lactams are presented whereby a carboxylic acid of the formula HOOC------OR---NH-LG, wherein OR is an organic moiety and LG is a leaving group, is reacted with an acid, such as an organic acid, in particular ...
|
|
WO/2015/060402A1 |
Provided are a novel production method for trifluoromethanesulfonanilides, which are useful as herbicides, etc., and intermediates therefor. Specifically provided are: an industrially-useful production method for producing a trifluorom...
|
|
WO/2015/055771A1 |
The present invention relates toaminotetralineand aminoindane derivatives of the formula (I) (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetralineand ami- noi...
|
|
WO/2015/042397A1 |
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associat...
|
|
WO/2015/034820A1 |
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowin...
|
|
WO/2015/030189A1 |
Provided is a compound which exhibits bone formation acceleration activity (and/or bone resorption suppression activity). The compound is either a compound having a general formula (I) (wherein the substituents are as defined in the desc...
|
|
WO/2015/026914A1 |
The present invention relates to azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2015/023839A1 |
The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2015/021109A1 |
The present invention relates to disubstituted aryl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2015/010297A1 |
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
|
|
WO/2015/002230A1 |
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)
|
|
WO/2014/203691A1 |
Provided are a platinum complex that has an excellent antitumor effect and reduced toxicity such as myelosuppression, and a medicine containing the same. A platinum complex derivative represented by general formula (1) [wherein: R1 and R...
|
|
WO/2014/165075A1 |
Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts and esters thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by th...
|
|
WO/2014/160783A1 |
Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Park...
|
|
WO/2014/160649A1 |
This invention pertains generally to antibacterial organic compounds of Formula I as described herein, and pharmaceutical compositions containing such compounds. In certain aspects, the invention pertains to treating infections caused by...
|
|
WO/2014/146994A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2014/152444A1 |
Proivded herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDACl, HDAC2, and HDAC3).
|
|
WO/2014/146491A1 |
The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
|
|
WO/2014/139410A1 |
Disclosed is a method for preparing 3-amino-3-iminopropanoic acid-1-(diphenylmethyl)-3-azetidinyl ester acetate used as intermediate of azelnidipine. In such method, 1-diphenylmethyl-3-azetidin-ol and cyano acetic acid used as raw materi...
|
|
WO/2014/139963A1 |
The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inven...
|
|
WO/2014/129744A1 |
The present invention relates to: a novel four-membered cyclic nitrogen compound capable of being used as an agent for treating or preventing depression, mental disorders, premature ejaculation or neuropathic pain by highly preventing th...
|
|
WO/2014/124560A1 |
Provided herein are compounds of the formula I: (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions contain...
|
|
WO/2014/126802A1 |
The present invention relates to alkene azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/127033A1 |
The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
|
|
WO/2014/122222A1 |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other d...
|
|
WO/2014/098098A1 |
A compound represented by formula (I) [wherein each symbol is as defined in the description] has a TRPA1 antagonistic activity, and the compound and a medicine containing the compound are useful for the prevention or treatment of disease...
|
|
WO/2014/097257A1 |
The subject of the present invention is a method of preparation of (1'R,3R,4R)-4-acetoxy-3-(1'- (tert-butyl-dimethylsilyloxy)ethyl)-2-azetidinone defined by the formula (1) which is a basic chiral building block in the synthesis of carba...
|
|
WO/2014/089810A1 |
A method for preparing a carbapenem intermediate β-methyl-ADC-8, comprising: (1) a reaction of 2-haloacrylate compounds with N-substituted-4-acyloxyazetidinone under the effect of a metal, or a Mannich reaction of a propionate compound ...
|
|
WO/2014/087298A1 |
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...
|
|
WO/2014/081756A1 |
Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
|
|
WO/2014/074848A1 |
Compositions comprising compounds of general formula (I) that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.
|
|
WO/2014/072903A1 |
The invention relates to novel aminomethyl-phenol derivatives of formula I wherein R1 to R4, X, A and B are as defined for formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention als...
|
|
WO/2014/061693A1 |
The purpose of the present invention is to provide a novel compound that has an ACC2 inhibitory activity. Also provided is a medicinal composition containing the compound. A compound represented by formula (I) or a pharmaceutically accep...
|
